Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get

Research output: Contribution to journalArticlepeer-review

Abstract

Heat shock proteins (HSPs) are highly conserved, stress-induced proteins that function as chaperones stabilizing and delivering peptides. In several preclinical studies, tumor derived HSP-peptide complexes (HSPPCs) have been shown to induce immunity against several malignancies. HSP-based vaccines, indeed, work across tumor types, bypassing the need for the identification of the single immunogenic peptide and thus emerging as a class of tumor- and patient-specific vaccines. HSPPC-96-based vaccine vitespen® (formerly Oncophage®) is the first autologous cancer vaccine made from individual patients' tumors which not only confirmed its activity in different malignancies (e.g., gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin's lymphoma and chronic myelogenous leukemia), but was also successfully tested in phase III clinical trials in melanoma and kidney cancer. HSPPC-96-based vaccine also demonstrated an excellent safety profile with almost no toxicity. HSP-based vaccines are emerging as a novel therapeutic approach with a suggestive role in cancer therapy.

Original languageEnglish
Pages (from-to)727-737
Number of pages11
JournalHuman Vaccines
Volume5
Issue number11
DOIs
Publication statusPublished - 2009

Keywords

  • HSP
  • HSP-based vaccine
  • Melanoma
  • Oncophage
  • Vitespen

ASJC Scopus subject areas

  • Immunology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get'. Together they form a unique fingerprint.

Cite this